A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes

Mine Harada, Tsunefumi Shibuya, Takanori Teshima, Masahiro Murakawa, Takashi Okamura, Yoshiyuki Niho, Hisashi Gondo, Shin Hayashi, Koichi Akashi, Kazuo Tamura, Shigeyoshi Makino, Hideyo Natori, Koichiro Egami, Shusuke Hisano, Eiji Morioka, Shuichi Taniguchi, Kazuo Yamazaki, Yujiro Yamano, Fusayuki Omori

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Fingerprint

Dive into the research topics of 'A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes'. Together they form a unique fingerprint.

Medicine & Life Sciences